Anup Trikkanad
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Research Areas
Biography and Research Information
OverviewAI-generated summary
Anup Trikkanad's research focuses on medical case reports, particularly investigating the mechanisms behind new-onset sarcoidosis observed during B-cell maturation antigen (BCMA)-directed T-cell engager therapy. Trikkanad's work has explored the presentation of this condition in patients with relapsed/refractory high-risk multiple myeloma undergoing treatment with teclistamab. This research involves collaboration with Sharmilan Thanendrarajan, Logan Meurer, and Shoon Lei Oo at the University of Arkansas for Medical Sciences, with whom Trikkanad has co-authored publications. Trikkanad's scholarly output includes one publication and one citation, with an h-index of 1, and the researcher has been active recently, with the most recent publication in 2026.
Metrics
- h-index: 1
- Publications: 1
- Citations: 1
Selected Publications
-
New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight (2026)
Collaboration Network
Top Collaborators
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
Similar Researchers
Based on overlapping research topics